Philip Morris Moldova Introduces IQOS ILUMA Smokeless Tobacco Device

PMI by 2FIRSTS.ai

Mar.11.2024

Philip Morris Moldova Introduces IQOS ILUMA Smokeless Tobacco Device

Philip Morris Moldova launches new IQOS ILUMA heated tobacco device to expand smoke-free product range, targeting adult smokers and nicotine consumers.

According to reports from local media, Philip Morris International (PMI) Moldova has launched the latest heated tobacco device IQOS ILUMA in the country to expand its portfolio of smoke-free products. This device is primarily targeted towards adult smokers and nicotine consumers.

Elena Naumenko, General Manager of Philip Morris International (PMI) in Moldova, added: "The decision to introduce IQOS ILUMA in Moldova is an important step for us, as each product launch requires a significant amount of resources and effort. With the expansion of our smoke-free product portfolio, we have increased our local team, expanded our sales network, and built the necessary infrastructure. Just this year alone, we have invested approximately $1 million in the launch of the latest smoke-free device in the local market.

Philip Morris International (PMI) estimates that more than 20 million adult smokers around the world have completely abandoned tobacco products in favor of using PMI's smoke-free alternatives.

The IQOS ILUMA is equipped with SMARTCORE INDUCTION SYSTEM™ technology, which heats tobacco from the inside without the use of heating blades. This means the device never needs cleaning as there is no tobacco residue inside.

It has been reported that the smoke-free products developed by Philip Morris International (PMI) have been rolled out in over 80 markets worldwide.

References:

[1] Philip Morris Moldova расширяет свое присутствие на рынке, дополняя портфолио бездымных продуктов

Also Read:

[1] Evgeny Nikolsky Appointed as JTI Romania, Moldova, Bulgaria GM

[2] Estonia May Stop Selling PMI, JTI Products Due to Their Presence in Russia

[3] PMI to Build Cigarette Factory in Tanzania

[4] PMI Launches IQOS ILUMA in Colombia

#Europe #Products #IQOS ILUMA #Heated tobacco products #Vaping devices #E-cigarette devices #Moldova

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn

Notice

1. This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2. The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3. This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4. Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

Copyright

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

AI Assistance Disclaimer

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

NZ Issues National High Alert on Etomidate-Laced Vapes After Hospitalisations

New Zealand’s High Alert drug harm monitoring system has issued a public High Alert warning after multiple hospitalisations linked to illicit vape pods containing the anaesthetic etomidate. Known on the street as space oil, k-pods, or eto, these vapes were first detected in January 2025. Customs has since seized additional samples, and clinics nationwide report rising cases of poisoning and hypoglycaemia.

Nov.04 by 2FIRSTS.ai

iMiracle and VPR Reach Preliminary Settlement in ‘Elf’ Trademark Dispute, Potentially Ending Three-Year Legal Battle

According to Law360, VPR Brands and iMiracle have filed a joint notice in federal court in Florida stating that they have signed a settlement term sheet and plan to finalize a global settlement within 30 days that would resolve multiple lawsuits. The dispute, which began in 2022 and centers on the “Elf” trademark, has involved injunctions, counterclaims and a key ruling by the Federal Circuit overturning a lower court’s order.

Dec.11 by 2FIRSTS.ai

UK Experts Raise Concerns Over High-Dose Nicotine Pouches Amid Rising Sales

According to The Guardian, health experts in the UK are warning about the potential health effects of high-dose nicotine pouches as their sales continue to rise. Recent studies show teenagers reporting nicotine rushes, sickness and fainting, while researchers say packaging and marketing increasingly appeal to younger age groups. Although viewed as less harmful than cigarettes, experts remain concerned about their use among non-smokers, especially adolescents.

Nov.13 by 2FIRSTS.ai

Vape Company Takes FDA to Court for Stalling Premarket Decision for Half a Decade

California-based vape manufacturer Schwartz E-Liquid (USA Vape Lab) has sued the U.S. Food and Drug Administration (FDA) in federal court, alleging the agency unlawfully failed to issue a decision on its premarket application for flavored e-cigarette products for more than five years. The company is seeking a court order compelling the FDA to act within 90 days.